المؤلفون: Park, H, Garrido-Laguna, I, Naing, A, Fu, S, Falchook, GS, Piha-Paul, SA, Wheler, JJ, Hong, DS, Tsimberidou, AM, Subbiah, V, Zinner, RG, Kaseb, AO, Patel, S, Fanale, MA, Velez-Bravo, VM, Meric-Bernstam, F, Kurzrock, R, Janku, F

المصدر: Oncotarget, vol 7, iss 41
Park, H; Garrido-Laguna, I; Naing, A; Fu, S; Falchook, GS; Piha-Paul, SA; et al.(2016). Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. ONCOTARGET, 7(41), 67521-67531. doi: 10.18632/oncotarget.11750. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/1dp7g79p

مصطلحات موضوعية: Sirolimus, Adult, Male, Vorinostat, Maximum Tolerated Dose, Adolescent, TOR Serine-Threonine Kinases, Oncology and Carcinogenesis, Middle Aged, phase I, Hydroxamic Acids, Histone Deacetylase Inhibitors, Young Adult, HDAC, hemic and lymphatic diseases, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, mTOR, Humans, Female, Aged

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::512319f3ff14299dfb14919f0d8072de
https://escholarship.org/uc/item/1dp7g79p

المؤلفون: Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org., Park H; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Internal Medicine (Division of Oncology), Washington University School of Medicine, St. Louis, Missouri., Call SG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Madwani K; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Oki Y; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Velez-Bravo VM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Barnes TG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hagemeister FB; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Falchook GS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garrido-Laguna I; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shpall EJ; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kurzrock R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fanale MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Nov 01; Vol. 26 (21), pp. 5579-5587. Date of Electronic Publication: 2020 Oct 14.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Everolimus/*administration & dosage , Histone Deacetylases/*genetics , Hodgkin Disease/*drug therapy , Sirolimus/*administration & dosage , TOR Serine-Threonine Kinases/*genetics , Vorinostat/*administration & dosage, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols ; Brentuximab Vedotin/administration & dosage ; Dose-Response Relationship, Drug ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/pathology ; Everolimus/adverse effects ; Female ; Hematopoietic Stem Cell Transplantation ; Histone Deacetylase Inhibitors/administration & dosage ; Histone Deacetylase Inhibitors/adverse effects ; Humans ; Male ; Middle Aged ; Recurrence ; Sirolimus/adverse effects ; Stem Cell Transplantation ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Vorinostat/adverse effects ; Young Adult

المؤلفون: Park H; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Internal Medicine (Division of Oncology), Washington University School of Medicine, St. Louis, MO, USA., Garrido-Laguna I; Department of Internal Medicine (Division of Oncology), Huntsman Cancer Institute and University of Utah School of Medicine, Salt Lake City, UT, USA., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Falchook GS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Sarah Cannon Research Institute at HealthONE, Denver, CO, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wheler JJ; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zinner RG; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Medical Oncology, Thomas Jefferson University and Jefferson University Hospitals, Philadelphia, PA, USA., Kaseb AO; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel S; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fanale MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Velez-Bravo VM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kurzrock R; Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, San Diego, CA, USA., Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

المصدر: Oncotarget [Oncotarget] 2016 Oct 11; Vol. 7 (41), pp. 67521-67531.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Neoplasms/*drug therapy, Adolescent ; Adult ; Aged ; Female ; Histone Deacetylase Inhibitors/therapeutic use ; Humans ; Hydroxamic Acids/administration & dosage ; Hydroxamic Acids/adverse effects ; Male ; Maximum Tolerated Dose ; Middle Aged ; Sirolimus/administration & dosage ; Sirolimus/adverse effects ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Vorinostat ; Young Adult